In the Phase 2 clinical trial (NEJM, 2023), retatrutide was administered subcutaneously at doses ranging from approximately 0.5 mg to 12 mg per week, with dose escalation under close medical supervision
According to NICE guidance (NG12), these red flags include unintentional weight loss, rectal bleeding, iron-deficiency anaemia, abdominal or rectal mass, persistent change in bowel habit (to looser or more frequent stools) for more than 6 weeks in people aged 60 or over, and a family history of bowel or ovarian cancer
Hims & Hers GLP-1 injectable not evaluated by FDA, class action claims Hims & Hers compounded semaglutide products have not been meaningfully tested for safety or effectiveness or evaluated by the U.S
If you have commercial drug insurance, you may be eligible for the savings card program, even if your insurance doesnt cover the medication (other conditions may apply)
Not all compounding pharmacies offer the levocarnitine combination
A healthcare provider will monitor progress and side effects to determine the appropriate maintenance dose